Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 17 Jun 2018 Results assessing the safety and efficacy of Venetoclax monotherapy in previously treated patients with Waldenstrom Macroglobulinemia, presented at the 23rd Congress of the European Haematology Association.
- 26 Feb 2018 Planned End Date changed from 1 Feb 2023 to 1 Feb 2022.
- 26 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.